{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["111(1)"],"submitter":["Wang W"],"pubmed_abstract":["<h4>Background</h4>Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) cancers are associated with an increased number of somatic mutations, which can render tumors more susceptible to immune checkpoint blockade. However, a comprehensive evaluation of the efficacy profile of immune checkpoint inhibitors in this patient population across multiple cancer types is lacking. This study aims to address this knowledge gap by synthesizing data from phase I-III clinical trials.<h4>Methods</h4>A systematic search was conducted in PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Google Scholar from inception until June 2024. Eligible studies included randomized controlled trials (RCTs), nonrandomized comparative studies, and single-arm trials investigat"],"journal":["International journal of surgery (London, England)"],"pagination":["1357-1372"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11745646"],"repository":["biostudies-literature"],"pubmed_title":["Immune checkpoint inhibitors for patients with mismatch repair deficient or microsatellite instability-high advanced cancers: a meta-analysis of phase I-III clinical trials."],"pmcid":["PMC11745646"],"pubmed_authors":["Jiang J","Jiang Z","Zhou N","Zhai X","Mei Z","Wang W","Chen Y","Qu Y","Bulibu G","Tang Y","Saifuding K"],"additional_accession":[]},"is_claimable":false,"name":"Immune checkpoint inhibitors for patients with mismatch repair deficient or microsatellite instability-high advanced cancers: a meta-analysis of phase I-III clinical trials.","description":"<h4>Background</h4>Mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) cancers are associated with an increased number of somatic mutations, which can render tumors more susceptible to immune checkpoint blockade. However, a comprehensive evaluation of the efficacy profile of immune checkpoint inhibitors in this patient population across multiple cancer types is lacking. This study aims to address this knowledge gap by synthesizing data from phase I-III clinical trials.<h4>Methods</h4>A systematic search was conducted in PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Google Scholar from inception until June 2024. Eligible studies included randomized controlled trials (RCTs), nonrandomized comparative studies, and single-arm trials investigat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-06T23:35:04.124Z","creation":"2026-06-06T03:11:08.542Z"},"accession":"S-EPMC11745646","cross_references":{"pubmed":["39166943"],"doi":["10.1097/JS9.0000000000002007"]}}